Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Overcoming Therapeutic Resistance in Lymphoma

EF 2013-14

Résumé
About 1 in 30 Canadians develop lymphoma, and resistance to chemotherapy is a problem for many of these patients. Since responses to chemotherapy depend on tumour biology, previous work in our laboratory consisted of sequencing more than 300 lymphomas at diagnosis and at relapse. This enabled our lab to identify FAS (CD95) as a potential tumour suppressor, and to discover that mutant FAS is associated with therapeutic resistance. FAS is a cell surface death receptor that once activated by its FAS ligand (FASL), initiates apoptosis (cell death) through the extrinsic apoptotic pathway. The most common FAS mutation in the lymphomas screened was found to be a dominant negative allele; meaning only one copy of the FAS gene needs to be mutated in order to have the negative effect on the cell. Moreover, the protein product of this mutated FAS gene is truncated and inhibits FAS-mediated cell death. This mutant allele was found to induce resistance to Doxorubicin (a main chemotherapeutic agent used in the treatment of lymphoma) in a mouse model of Fas-mutant lymphoma. This mutant FAS allele, however, had no effect on chemo-sensitivity in cultured lymphoma cell lines, in vitro. The first objective of my research project was to confirm that our mouse model of Fas-mutant lymphoma is representative of the human disease. Since this first objective was accomplished, my next objective is to use our mouse model of Fas-mutant lymphoma to test if existing “novel” therapies could potentially be used to treat patients with FAS-mutant lymphomas. My third objective is to address the differences observed between the response of the FAS-mutant cells in vivo and in vitro, by ultimately defining the role of the immune system in killing lymphomas after exposure to chemotherapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311854
Name
Totten Stephanie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Overcoming Therapeutic Resistance in Lymphoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apoptosis; Chemotherapeutic Resistance; Chemotherapy; Fas Receptor; Lymphoma
Abstract
About 1 in 30 Canadians develop lymphoma, and resistance to chemotherapy is a problem for many of these patients. Since responses to chemotherapy depend on tumour biology, previous work in our laboratory consisted of sequencing more than 300 lymphomas at diagnosis and at relapse. This enabled our lab to identify FAS (CD95) as a potential tumour suppressor, and to discover that mutant FAS is associated with therapeutic resistance. FAS is a cell surface death receptor that once activated by its FAS ligand (FASL), initiates apoptosis (cell death) through the extrinsic apoptotic pathway. The most common FAS mutation in the lymphomas screened was found to be a dominant negative allele; meaning only one copy of the FAS gene needs to be mutated in order to have the negative effect on the cell. Moreover, the protein product of this mutated FAS gene is truncated and inhibits FAS-mediated cell death. This mutant allele was found to induce resistance to Doxorubicin (a main chemotherapeutic agent used in the treatment of lymphoma) in a mouse model of Fas-mutant lymphoma. This mutant FAS allele, however, had no effect on chemo-sensitivity in cultured lymphoma cell lines, in vitro. The first objective of my research project was to confirm that our mouse model of Fas-mutant lymphoma is representative of the human disease. Since this first objective was accomplished, my next objective is to use our mouse model of Fas-mutant lymphoma to test if existing “novel” therapies could potentially be used to treat patients with FAS-mutant lymphomas. My third objective is to address the differences observed between the response of the FAS-mutant cells in vivo and in vitro, by ultimately defining the role of the immune system in killing lymphomas after exposure to chemotherapy.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Totten, Stephanie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~